The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
Abstract
Pyruvate kinase M2 (PKM2), a key rate-limiting enzyme of glycolysis, is a critical regulator in tumor metabolism. PKM2 has been demonstrated to overexpressed in various cancers and promoted proliferation and metastasis of tumor cells. The errant expression of PKM2 has inspired people to investigate the function of PKM2 and the therapeutic potential in cancer. In addition, some studies have shown that the upregulation of PKM2 in tumor tissues is associated with the altered expression of lncRNAs and the poor survival. Therefore, researchers have begun to unravel the specific molecular mechanisms of lncRNA-mediated PKM2 expression in cancer metabolism. As the tumor microenvironment (TME) is essential in tumor development, it is necessary to identify the role of PKM2 in TME. In this review, we will introduce the role of PKM2 in different cancers as well as TME, and summarize the molecular mechanism of PKM2-related lncRNAs in cancer metabolism. We expect that this work will lead to a better understanding of the molecular mechanisms of PKM2 that may help in developing therapeutic strategies in clinic for researchers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Liu, X., Zhu, Q., Guo, Y., Xiao, Z., Hu, L., & Xu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109069 · Cited by 100
Self-citationRetractedLi, C., Zhao, Z., Zhou, Z., & Liu, R. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3178-4 · Cited by 86
RetractedChen, S., Chen, X., Shan, T., Ma, J., Lin, W., Li, W., & Kang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22555 · Cited by 62
Self-citationRetractedLang, N., Wang, C., Zhao, J., Shi, F., Wu, T., & Cao, H. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10944 · Cited by 45
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
The functions and unique features of long intergenic non-coding RNA
Ransohoff, J. D., Wei, Y., & Khavari, P. A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.104 · Cited by 1,330
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z. (2011) · Nature · doi:10.1038/nature10598 · Cited by 1,028
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis
Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K., & Lu, Z. (2012) · Cell · doi:10.1016/j.cell.2012.07.018 · Cited by 846
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816
Pyruvate kinase type M2 and its role in tumor growth and spreading
Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.009 · Cited by 812
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein Kinase
Gao, X., Wang, H., Yang, J. J., Liu, X., & Liu, Z.-R. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.001 · Cited by 772
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549
Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA
Wu, P., Mo, Y., Peng, M., Tang, T., Zhong, Y., Deng, X., Xiong, F., Guo, C., Wu, X., Li, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1147-3 · Cited by 540
Noguchi, T., Inoue, H., & Tanaka, T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67091-7 · Cited by 537
Pucino, V., Certo, M., Bulusu, V., Cucchi, D., Goldmann, K., Pontarini, E., Haas, R., Smith, J., Headland, S. E., Blighe, K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.004 · Cited by 530
PKM2, cancer metabolism, and the road ahead
Dayton, T. L., Jacks, T., & Vander Heiden, M. G. (2016) · The EMBO Reports · doi:10.15252/embr.201643300 · Cited by 515
Wei, J., Long, L., Yang, K., Guy, C., Shrestha, S., Chen, Z., Wu, C., Vogel, P., Neale, G., Green, D. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3365 · Cited by 470
TANAKA, T., HARANO, Y., SUE, F., & MORIMURA, H. (1967) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a128639 · Cited by 454
Szabo, C., & Papapetropoulos, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.014050 · Cited by 423
Ye, J., Mancuso, A., Tong, X., Ward, P. S., Fan, J., Rabinowitz, J. D., & Thompson, C. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204176109 · Cited by 410
Pharmacological properties and derivatives of shikonin—A review in recent years
Guo, C., He, J., Song, X., Tan, L., Wang, M., Jiang, P., Li, Y., Cao, Z., & Peng, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104463 · Cited by 374
Self-citationWei, Y., Wang, D., Jin, F., Bian, Z., Li, L., Liang, H., Li, M., Shi, L., Pan, C., Zhu, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms14041 · Cited by 315
Self-citationBian, Z., Zhang, J., Li, M., Feng, Y., Wang, X., Zhang, J., Yao, S., Jin, G., Du, J., Han, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2967 · Cited by 305
Angiari, S., Runtsch, M. C., Sutton, C. E., Palsson-McDermott, E. M., Kelly, B., Rana, N., Kane, H., Papadopoulou, G., Pearce, E. L., Mills, K. H. G., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.015 · Cited by 305
PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation
Damasceno, L. E. A., Prado, D. S., Veras, F. P., Fonseca, M. M., Toller-Kawahisa, J. E., Rosa, M. H., Públio, G. A., Martins, T. V., Ramalho, F. S., Waisman, A., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190613 · Cited by 284
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation
Lunt, S. Y., Muralidhar, V., Hosios, A. M., Israelsen, W. J., Gui, D. Y., Newhouse, L., Ogrodzinski, M., Hecht, V., Xu, K., Acevedo, P. N. M., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.10.027 · Cited by 257
Prigione, A., Rohwer, N., Hoffmann, S., Mlody, B., Drews, K., Bukowiecki, R., Blümlein, K., Wanker, E. E., Ralser, M., Cramer, T., et al. (2014) · Stem Cells · doi:10.1002/stem.1552 · Cited by 254
Hou, P.-P., Luo, L.-J., Chen, H.-Z., Chen, Q.-T., Bian, X.-L., Wu, S.-F., Zhou, J.-X., Zhao, W.-X., Liu, J.-M., Wang, X.-M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.004 · Cited by 253
PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation
Li, T., Han, J., Jia, L., Hu, X., Chen, L., & Wang, Y. (2019) · Protein & Cell · doi:10.1007/s13238-019-0618-z · Cited by 245
Danilova, L., Ho, W. J., Zhu, Q., Vithayathil, T., De Jesus-Acosta, A., Azad, N. S., Laheru, D. A., Fertig, E. J., Anders, R., Jaffee, E. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0822 · Cited by 242
PKM2 Regulates Chromosome Segregation and Mitosis Progression of Tumor Cells
Jiang, Y., Li, X., Yang, W., Hawke, D. H., Zheng, Y., Xia, Y., Aldape, K., Wei, C., Guo, F., Chen, Y., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.001 · Cited by 237
Xu, F., Guo, M., Huang, W., Feng, L., Zhu, J., Luo, K., Gao, J., Zheng, B., Kong, L.-D., Pang, T., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101634 · Cited by 196
Luan, X., & Wang, Y. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e95 · Cited by 185
Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis
Alvarez-Dominguez, J. R., & Lodish, H. F. (2017) · Blood · doi:10.1182/blood-2017-06-788695 · Cited by 181
Keller, K. E., Doctor, Z. M., Dwyer, Z. W., & Lee, Y.-S. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.015 · Cited by 179
Hsu, M.-C., & Hung, W.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0791-3 · Cited by 179
Cao, Y., Rathmell, J. C., & Macintyre, A. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104104 · Cited by 177
Dai, J., Escara-Wilke, J., Keller, J. M., Jung, Y., Taichman, R. S., Pienta, K. J., & Keller, E. T. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190158 · Cited by 176
Palsson-McDermott, E. M., Dyck, L., Zasłona, Z., Menon, D., McGettrick, A. F., Mills, K. H. G., & O’Neill, L. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01300 · Cited by 173
Zheng, Y.-L., Li, L., Jia, Y.-X., Zhang, B.-Z., Li, J.-C., Zhu, Y.-H., Li, M.-Q., He, J.-Z., Zeng, T.-T., Ban, X.-J., et al. (2019) · Theranostics · doi:10.7150/thno.28992 · Cited by 166
Wu, H.-J., Hao, M., Yeo, S. K., & Guan, J.-L. (2020) · Oncogene · doi:10.1038/s41388-020-1162-2 · Cited by 165
Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma
Dayton, T. L., Gocheva, V., Miller, K. M., Israelsen, W. J., Bhutkar, A. J., Clish, C. B., Davidson, S. M., Luengo, A., Bronson, R. T., Jacks, T., et al. (2016) · Genes & Development · doi:10.1101/gad.278549.116 · Cited by 160
Wu, X., Zhou, Z., Xu, S., Liao, C., Chen, X., Li, B., Peng, J., Li, D., & Yang, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.004 · Cited by 156
Self-citationBenserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
Li, W., Zheng, M., Wu, S., Gao, S., Yang, M., Li, Z., Min, Q., Sun, W., Chen, L., Xiang, G., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0530-4 · Cited by 144
Gao, C., Hou, G., Liu, J., Ru, T., Xu, Y., Zhao, S., Ye, H., Zhang, L., Chen, K., Guo, Y., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912489 · Cited by 143
Self-citationGershon, T. R., Crowther, A., Tikunov, A. P., García, I., Annis, R. P., Yuan, H., Miller, C. R., Macdonald, J. M., Olson, J. M., & Deshmukh, M. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-2 · Cited by 134
Wan, L., Xia, T., Du, Y., Liu, J., Xie, Y., Zhang, Y., Guan, F., Wu, J., Wang, X., & Shi, C. (2019) · The FASEB Journal · doi:10.1096/fj.201802675r · Cited by 131
Allosteric Regulation of PKM2 Allows Cellular Adaptation to Different Physiological States
Gui, D. Y., Lewis, C. A., & Heiden, M. G. V. (2013) · Science Signaling · doi:10.1126/scisignal.2003925 · Cited by 129
Zheng, Q., Lin, Z., Xu, J., Lu, Y., Meng, Q., Wang, C., Yang, Y., Xin, X., Li, X., Pu, H., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0305-7 · Cited by 123
Giannoni, E., Taddei, M. L., Morandi, A., Comito, G., Calvani, M., Bianchini, F., Richichi, B., Raugei, G., Wong, N., Tang, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4448 · Cited by 119
Ning, X., Qi, H., Li, R., Li, Y., Jin, Y., McNutt, M. A., Liu, J., & Yin, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.064 · Cited by 118
Isolation and characterization of the human pyruvate kinase M gene
TAKENAKA, M., Noguchi, T., Sadahiro, S., Hirai, H., Yamada, K., Matsuda, T., Imai, E., & Tanaka, T. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb15991.x · Cited by 101
Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells
Untereiner, A. A., Pavlidou, A., Druzhyna, N., Papapetropoulos, A., Hellmich, M. R., & Szabó, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.007 · Cited by 101
Zheng, X., Zhou, Y., Chen, W., Chen, L., Lu, J., He, F., Xu, L., & Zhao, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495552 · Cited by 97
Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells
Stone, O. A., El-Brolosy, M. A., Wilhelm, K., Liu, X., Romão, A. M., Grillo, E., Lai, J. K. H., Günther, S., Jeratsch, S., Kuenne, C. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06406-8 · Cited by 96
The role of exosomes in metastasis and progression of melanoma
Gowda, R., Robertson, B. M., Iyer, S., Barry, J., Dinavahi, S. S., & Robertson, G. P. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101975 · Cited by 96
miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer
Li, H., Li, J., Jia, S., Wu, M., An, J., Zheng, Q., Zhang, W., & Lu, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5579 · Cited by 94
Brain aerobic glycolysis and motor adaptation learning
Shannon, B. J., Vaishnavi, S., Vlassenko, A. G., Shimony, J. S., Rutlin, J. R., & Raichle, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604977113 · Cited by 94
Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms
Li, G., Tang, W., & Yang, F. (2020) · Biotechnology Journal · doi:10.1002/biot.201900225 · Cited by 94
Kim, S., Jang, J.-Y., Koh, J., Kwon, D., Kim, Y. A., Paeng, J. C., Ock, C., Keam, B., Kim, M., Kim, T. M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1407-5 · Cited by 93
Méndez‐Lucas, A., Li, X., Hu, J., Che, L., Song, X., Jia, J., Wang, J., Xie, C., Driscoll, P. C., Tschaharganeh, D. F., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0498 · Cited by 91
Self-citationMohammad, G. H., Vassileva, V., Acedo, P., Damink, S. W. M. O., Malagó, M., Dhar, D. K., & Pereira, S. P. (2019) · Cancers · doi:10.3390/cancers11091372 · Cited by 91
Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment
Zhou, Y., Huang, Z., Su, J., Li, J., Zhao, S., Wu, L., Jiangling, Z., He, Y., Zhang, G., Tao, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32756 · Cited by 88
Self-citationCui, S., Yang, X., Zhang, L., Zhao, Y., & Yan, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.112 · Cited by 85
Druzhyna, N., Szczęsny, B., Oláh, G., Módis, K., Asimakopoulou, A., Pavlidou, A., Szoleczky, P., Gerő, D., Yanagi, K., Törő, G., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.016 · Cited by 83
Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis
Guan, Y., Huang, Q., Ai, Y.-L., Chen, Q.-T., Zhao, W., Wang, X., Wu, Q., & Chen, H. (2020) · Oncogene · doi:10.1038/s41388-020-1158-y · Cited by 82
Yang, H., Zhu, R., Zhao, X., Liu, L., Zhou, Z., Zhao, L., Liang, B., Ma, W., Zhao, J., Liu, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0764-z · Cited by 79
Lü, S., Deng, J., Liu, H., Liu, B., Yang, J., Miao, Y., Li, J., Wang, N., Jiang, C., Xu, Q., et al. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1645-6 · Cited by 75
Self-citationWitney, T. H., James, M. L., Shen, B., Chang, E., Pohling, C., Arksey, N., Höhne, A., Shuhendler, A. J., Park, J. H., Bodapati, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6117 · Cited by 67
Ren, R., Guo, J., Shi, J. Y., Tian, Y., Li, M., & Kang, H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29549 · Cited by 62
LncRNA‐TP53TG1 Participated in the Stress Response Under Glucose Deprivation in Glioma
Chen, X., Gao, Y., Li, D., Cao, Y., & Hao, B. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26175 · Cited by 61
Self-citationSuzuki, A., Puri, S., Leland, P., Puri, A., Moudgil, T. L., Fox, B. A., Puri, R. K., & Joshi, B. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217131 · Cited by 60
Activators of PKM2 in Cancer Metabolism
Warner, S. L., Carpenter, K. J., & Bearss, D. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.70 · Cited by 59
Ding, Y., Xue, Q., Liu, S., Hu, K., Wang, D., Wang, T., Li, Y., Guo, H., Hao, X., Ge, W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01328 · Cited by 58
Tech, K., Tikunov, A. P., Farooq, H., Morrissy, A. S., Meidinger, J., Fish, T., Green, S. C., Liu, H., Li, Y., Mungall, A. J. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3304 · Cited by 55
Self-citationGuo, J., Ren, R., Yao, X., Ye, Y., Sun, K., Lin, J., Wang, G., Guo, F., Xiao, J., & Xu, T. (2020) · Aging · doi:10.18632/aging.102866 · Cited by 55
Liu, Y., Xiaocui, H., Chen, Y., & Cao, D. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03647-z · Cited by 52
Hu, H., Tu, W., Chen, Y., Zhu, M., Jin, H., Huang, T., Zou, Z., & Xia, Q. (2020) · Journal of Cancer · doi:10.7150/jca.38981 · Cited by 52
Fan, X., Pei, S., Zhou, D., Zhou, P., Huang, Y., Hu, X., Li, T., Wang, Y., Huang, Z., & Li, N. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00516-0 · Cited by 52
Linc RNA ‐p21 suppresses development of human prostate cancer through inhibition of PKM 2
Wang, X., Xu, Y., Wang, X., Jiang, C., Han, S., Dong, K., Shen, M., & Xu, D. (2017) · Cell Proliferation · doi:10.1111/cpr.12395 · Cited by 51
PKM2 is not required for colon cancer initiated by APC loss
Lau, A. N., Israelsen, W. J., Roper, J., Sinnamon, M. J., Georgeon, L., Dayton, T. L., Hillis, A. L., Yilmaz, Ö. H., Vizio, D. D., Hung, K. E., et al. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0172-1 · Cited by 50
The role of pyruvate kinase M2 in anticancer therapeutic treatments (Review)
Su, Q., Luo, S., Tan, Q., Deng, J., Zhou, S., Peng, M., Tao, T., & Yang, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10948 · Cited by 49
Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells
Lin, Y., Zhai, H., Ouyang, Y., Lu, Z., Chu, C., He, Q., & Cao, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0845-7 · Cited by 48
Huang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48
Ning, X., Qi, H., Li, R., Jin, Y., McNutt, M. A., & Yin, Y. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1404591 · Cited by 47
Zhang, Y., & Tang, L. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0480-0 · Cited by 46
Wubben, T. J., Pawar, M. D., Weh, E., Smith, A. J. H., Sajjakulnukit, P., Zhang, L., Dai, L., Hager, H. M., Pai, M. P., Lyssiotis, C. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59999-w · Cited by 46
Petanidis, S., Domvri, K., Porpodis, Κ., Anestakis, D., Freitag, L., Hohenforst‐Schmidt, W., Tsavlis, D., & Zarogoulidis, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109461 · Cited by 43
PKM2 is not required for pancreatic ductal adenocarcinoma
Hillis, A. L., Lau, A. N., Devoe, C. X., Dayton, T. L., Danai, L. V., Vizio, D. D., & Heiden, M. G. V. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0188-1 · Cited by 39
Yu, W., Zhou, Y., Huang, R., Min, Z., & Ye, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194256 · Cited by 39
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma
Guo, C., Zhu, Q., Tou, F., Wen, X., Kuang, Y., & Hu, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5519-2 · Cited by 39
Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2
Fan, Z., He, J., Fu, T., Zhang, W., Yang, G., Qu, X.-D., Liu, R., Lv, L., & Wang, J. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.081 · Cited by 36
Yin, J., Shi, Z., Wei, W., Lu, C., Wei, Y., Yan, W., Li, R. Q., Zhang, J., You, Y., & Wang, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1149-7 · Cited by 36
Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis
Bluemlein, K., Glückmann, M., Grüning, N., Feichtinger, R. G., Krüger, A., Wamelink, M. M. C., Lehrach, H., Tate, S. A., Neureiter, D., Kofler, B., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.730 · Cited by 27
PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia
Liu, C., Zheng, M., Wang, T., Jiang, H., Fu, R., Wang, H., Ding, K., Zhou, Q., & Shao, Z. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1364165 · Cited by 22
Dai, H., Zeng, W., & Luo, H. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3464 · Cited by 14
LncRNA-NBAT-1 modulates esophageal cancer proliferation via PKM2.
Zhao, B., Cao, P., Hu, S., Li, F., Kong, K., & Zu, Y. (2019) · PubMed · Cited by 13
Totoń, E., Kędziora, I., Romaniuk-Drapała, A., Konieczna, N., Kaczmarek, M., Lisiak, N., Paszel-Jaworska, A., Rybska, A., Duszynska, W., Budzianowski, J., et al. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00008-x · Cited by 7
Cited by
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Self-citationTargeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Chaperone‐mediated autophagy: Molecular mechanisms, biological functions, and diseases
Yao, R., & Shen, J. (2023) · MedComm · doi:10.1002/mco2.347 · Cited by 111
Metadata
- Authors
- Zhu, S., Guo, Y., Zhang, X., Liu, H., Yin, M., Chen, X., & Peng, C.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 503
- Pages
- 240-248
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3109467285
- Cited by
- 266
- References
- 107
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.